Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH

J Nucl Med. 2005 May;46(5):900-1; author reply 901.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Body Burden
  • Bone Marrow / diagnostic imaging*
  • Bone Marrow / drug effects
  • Bone Marrow / radiation effects*
  • Chemotherapy, Adjuvant
  • Humans
  • Injections, Intramuscular
  • Iodine Radioisotopes / administration & dosage
  • Iodine Radioisotopes / adverse effects
  • Iodine Radioisotopes / pharmacokinetics
  • Iodine Radioisotopes / therapeutic use*
  • Male
  • Middle Aged
  • Platelet Count
  • Radiation Injuries / etiology
  • Radiation Injuries / prevention & control
  • Radiation Protection / methods
  • Radiometry / methods*
  • Radionuclide Imaging
  • Radiopharmaceuticals / administration & dosage
  • Radiopharmaceuticals / pharmacokinetics
  • Radiopharmaceuticals / therapeutic use
  • Radiotherapy Dosage
  • Recombinant Proteins / administration & dosage
  • Risk Assessment / methods*
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / metabolism
  • Thyroid Neoplasms / radiotherapy*
  • Thyroid Neoplasms / secondary
  • Thyrotropin / administration & dosage*
  • Thyrotropin / genetics
  • Treatment Outcome

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Recombinant Proteins
  • Thyrotropin